Before, Frank's immune cells could

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Before, Frank's immune cells could"

Transcription

1 Before, Frank's immune cells could barely recognize a prostate cancer cell. Now, they are focused on it.

2 Stimulate an immune response against advanced prostate cancer Extend median survival beyond 2 years in men with asymptomatic or minimally symptomatic metastatic CRPC. PROVENGE is the first in a new class of therapy that is designed to activate a patient s own antigen-presenting cells (APCs) to stimulate an immune response against prostate cancer. INDICATION: PROVENGE (sipuleucel-t) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. IMPORTANT SAFETY INFORMATION: PROVENGE is intended solely for autologous use and is not routinely tested for transmissible infectious diseases. In controlled clinical trials, serious adverse events reported in the PROVENGE group include acute infusion reactions (occurring within 1 day of infusion) and cerebrovascular events. Severe (Grade 3) acute infusion reactions were reported in 3.5% of patients in the PROVENGE group. Reactions included chills, fever, fatigue, asthenia, dyspnea, hypoxia, bronchospasm, dizziness, headache, hypertension, muscle ache, nausea, and vomiting. No Grade 4 or 5 acute infusion reactions were reported in patients in the PROVENGE group. The precise mechanism of action of PROVENGE is not known. The most common adverse events (incidence 15%) reported in the PROVENGE group are chills, fatigue, fever, back pain, nausea, joint ache, and headache. Please see Important Safety Information on page 6.

3 Making the decision to treat PROVENGE expands your therapeutic options Prostate cancer is the second leading cause of cancer-related death in men 1 In advanced prostate cancer, the disease will eventually progress in most men on androgen deprivation therapy 2 Metastatic CRPC is an aggressive disease with median survival from 15.5 months to * Vigilant monitoring and the resulting early diagnosis of metastatic disease provide an opportunity to treat these patients before they are symptomatic. Early identification of progression allows you to treat patients who have: Metastatic CRPC that is asymptomatic or minimally symptomatic, defined as: No moderate-to-severe prostate cancer related pain No use of narcotics for cancer-related pain Now with PROVENGE, you have another way to take action for your asymptomatic or minimally symptomatic metastatic CRPC patients. *Median survival range is based on the control group of recent clinical studies in this patient population. 1. American Cancer Society. Cancer Facts & Figures Atlanta, GA: American Cancer Society; Kantoff PW, Carroll PR, D Amico AV, eds. Prostate Cancer: Principles and Practice. Philadelphia, PA: Lippincott Williams & Wilkins; Kantoff PW, Higano CS, Shore ND, et al; for the IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363: Stimulate a Response Please see enclosed full Prescribing Information for PROVENGE. 2

4 Training the immune cells PROVENGE the first FDA-approved autologous cellular immunotherapy The active component of PROVENGE consists of a patient s own APCs that have been cultured with a recombinant antigen to stimulate the body s immune system against prostate cancer PROVENGE Proposed Mechanism of Action PROSTATIC ACID PHOSPHATASE (PAP) AN ANTIGEN 1 EXPRESSED IN MORE THAN 95% OF PROSTATE CANCERS 1 GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) AN IMMUNE-CELL ACTIVATOR PAP-GM-CSF ANTIGEN COMBINES WITH RESTING APC APC TAKES UP THE PAP-GM-CSF PAP-GM-CSF IS PROCESSED AND PRESENTED ON THE SURFACE OF THE APC ACTIVE T CELL INACTIVE T CELL INFUSE PATIENT T CELLS PROLIFERATE TO TARGET PROSTATE CANCER CELLS PROVENGE ACTIVATES T CELLS IN THE BODY PAP-GM-CSF LOADED APCs ARE NOW THE ACTIVE COMPONENT OF PROVENGE The precise mechanism of action of PROVENGE is not known. The precise mechanism of action of PROVENGE is not known. 1. Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol. 2002;117: Please see Important Safety Information on page 6.

5 Primary endpoint: overall survival The PROVENGE pivotal trial The pivotal trial was a randomized, double-blind, multicenter, controlled* Phase 3 trial of 512 patients with asymptomatic or minimally symptomatic metastatic CRPC Primary endpoint Overall survival Secondary endpoint Time to objective disease progression Trial Design 1 Asymptomatic or Minimally Symptomatic Metastatic CRPC (N=512) 2:1 PROVENGE Q2 weeks x 3 Control* Q2 weeks x 3 PROGRESSION Treated at Physician Discretion Treated at Physician Discretion Including Entry Into Phase 2, Open-Label Protocol SURVIVAL *Control was nonactivated, autologous, peripheral blood mononuclear cells. After independent confirmation of objective disease progression: All patients were treated at their physicians discretion Patients in the control group had the option to enter a Phase 2, open-label protocol Treatment An autologous immunotherapy made from cells that were cryopreserved at the time of control generation Participation 63.7% of patients in the control group entered the Phase 2 protocol 1. Kantoff PW, Higano CS, Shore ND, et al; for the IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363: Stimulate a Response Please see enclosed full Prescribing Information for PROVENGE. 4

6 Reporting results PROVENGE extends median survival beyond 2 years Reduction in risk of death: 22.5% for patients in the PROVENGE group compared with patients in the control* group (HR=0.775 [95% CI: 0.614, 0.979] P=.032) Overall Survival 1,2 100 PROVENGE (n=341) Control (n=171) 75 Reduction in risk of death: 22.5% Survival (%) months 25.8 months HR=0.775 (95% CI: 0.614, 0.979) P= Time From Randomization (Months) Data originally published in the New England Journal of Medicine: Kantoff PW, Higano CS, Shore ND, et al; for the IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363: An earlier Phase 3 trial (D9901) supports survival results: 25.9 months for patients in the PROVENGE group compared with 21.4 months for patients in the control group (HR=0.586 [95% CI: 0.388, 0.884] P=.010) Analyses of time to disease progression did not meet statistical significance in any Phase 3 study of PROVENGE *Control was nonactivated, autologous, peripheral blood mononuclear cells. In Study D9901, all patients were followed for survival; however, overall survival was not a prespecified endpoint. 1. PROVENGE [package insert]. Dendreon Corporation; April The Kantoff precise PW, Higano mechanism CS, Shore ND, of action et al; for of the PROVENGE IMPACT Study Investigators. is not known. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363: Please see Important Safety Information on page 6.

7 Extending survival PROVENGE helps your patients continue their fight against advanced prostate cancer Survival probabilities: 1, 2, 3, and 4 years 1 Kaplan-Meier Survival Rate Estimates in the Pivotal Trial 1 Percentage of Patients Alive: ITT Population (95% CI) 1 year 2 years 3 years 4 years PROVENGE 81.1 (76.9, 85.3) n= (46.4, 57.7) n= (25.7, 37.8) n= (14.0, 26.9) n=14 Control 72.4 (65.6, 79.1) n= (33.5, 49.9) n= (15.5, 30.5) n= (8.5, 23.4) n= Percentage Increase in PROVENGE Group vs Control Group* year 2 years 3 years 4 years *(Percent PROVENGE percent control)/percent control. INDICATION: PROVENGE (sipuleucel-t) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. IMPORTANT SAFETY INFORMATION: PROVENGE is intended solely for autologous use and is not routinely tested for transmissible infectious diseases. In controlled clinical trials, serious adverse events reported in the PROVENGE group include acute infusion reactions (occurring within 1 day of infusion) and cerebrovascular events. Severe (Grade 3) acute infusion reactions were reported in 3.5% of patients in the PROVENGE group. Reactions included chills, fever, fatigue, asthenia, dyspnea, hypoxia, bronchospasm, dizziness, headache, hypertension, muscle ache, nausea, and vomiting. No Grade 4 or 5 acute infusion reactions were reported in patients in the PROVENGE group. The most common adverse events (incidence 15%) reported in the PROVENGE group are chills, fatigue, fever, back pain, nausea, joint ache, and headache. 1. Data on file. Dendreon Corporation. Stimulate a Response Please see enclosed full Prescribing Information for PROVENGE. 6

8 Analyzing safety With PROVENGE, the most common adverse events are primarily mild or moderate For 67.4% of patients reporting adverse events in the PROVENGE group, these events were mild or moderate. Most Common Adverse Events 1 * ADVERSE EVENT Chills Fatigue PROVENGE (n=601) (%) ANY GRADE Control (n=303) (%) The most common adverse events ( 15%) reported in the PROVENGE group are chills, fatigue, fever, back pain, nausea, joint ache, and headache. Fever Back pain Nausea Joint ache Headache * All grades reported in 15% of patients randomized to PROVENGE. The safety analysis is based on 601 prostate cancer patients in the PROVENGE group who underwent at least 1 leukapheresis procedure in Phase 3 clinical trials. Control was nonactivated, autologous, peripheral blood mononuclear cells. Acute infusion reactions: Acute infusion reactions (occurring within 1 day of infusion) were reported in 71.2% of patients in the PROVENGE group In 95.1% of patients, acute infusion reactions were mild or moderate The most common acute infusion reactions ( 20%) were chills, fever, and fatigue Fevers (71.9%) and chills (89.0%) generally resolved within 2 days 1.2% of patients in the PROVENGE group were hospitalized within 1 day of infusion for management of acute infusion reactions No Grade 4 or 5 acute infusion reactions were reported in patients in the PROVENGE group The precise mechanism of action of PROVENGE is not known. 1. PROVENGE [package insert]. Dendreon Corporation; April Please see Important Safety Information on page 6.

9 Considering the data A demonstrated safety profile In the PROVENGE group: Grade 3 adverse events were reported in 23.6% of patients compared with 25.1% of patients in the control group Grade 4 adverse events were reported in 4.0% of patients compared with 3.3% of patients in the control group Grade 5 adverse events were reported in 3.3% of patients compared with 3.6% of patients in the control group Serious adverse events included acute infusion reactions and cerebrovascular events Cerebrovascular events, including hemorrhagic and ischemic strokes, were reported in 3.5% of patients compared with 2.6% of patients in the control group Grades 3 5 Adverse Events 1,2 * ADVERSE EVENT Any adverse event Back pain Chills Anemia Joint ache Cerebrovascular accident Dyspnea Spinal cord compression Pain Asthenia Fatigue Hematuria Fever PROVENGE (n=601) (%) GRADES 3 5 Control (n=303) (%) *Reported in 1% of patients in the PROVENGE group. Control was nonactivated, autologous, peripheral blood mononuclear cells. Only 1.5% of patients in the pivotal trial discontinued treatment with PROVENGE due to adverse events. 1. PROVENGE [package insert]. Dendreon Corporation; April Data on file. Dendreon Corporation. Stimulate a Response Please see enclosed full Prescribing Information for PROVENGE. 8

10 Knowing who to treat Recognizing the PROVENGE patient PROVENGE is indicated for men with: Metastatic CRPC Asymptomatic or minimally symptomatic disease, defined as: No moderate-to-severe prostate cancer related pain No use of narcotics for cancer-related pain Certain additional criteria from the PROVENGE pivotal trial for consideration: No visceral (lung, liver, or brain) metastases ECOG Performance Status 0 or 1 No treatment with chemotherapy in at least the previous 3 months No treatment within 28 days with systemic corticosteroids The precise mechanism of action of PROVENGE is not known. 9 Please see Important Safety Information on page 6.

11 Expanding options for your patients Creating a new opportunity in your treatment of advanced prostate cancer NCCN Guidelines: PROVENGE Included for Treatment of Advanced Prostate Cancer 1 ADT Progression M1 * Asymptomatic or minimally symptomatic with ECOG 0-1 Asymptomatic Symptomatic Visceral disease PROVENGE (sipuleucel-t) Secondary hormone therapy Clinical trial Docetaxel Mitoxantrone Palliative radiotherapy or radionuclide for symptomatic bone metastases Clinical trial ADT=androgen deprivation therapy. *M1=Distant metastasis. Maintain castrate serum levels of testosterone and use denosumab or zoledronic acid if there are bone metastases. Cabazitaxel Salvage chemotherapy Docetaxel rechallenge Mitoxantrone Secondary hormone therapy Clinical trial Adapted from NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. V Men with less advanced disease (no or minimal symptoms) should consider immunotherapy with PROVENGE; men who are symptomatic should be considered for chemotherapy. NCCN Guidelines 1 PROVENGE did not preclude use of subsequent therapies. In the pivotal trial, 81.8% of patients in the PROVENGE group received additional anticancer treatments 2 1. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. V National Comprehensive Cancer Network Web site. Accessed December 14, Kantoff PW, Higano CS, Shore ND, et al; for the IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration resistant prostate cancer. N Engl J Med. 2010;363: Stimulate a Response Please see enclosed full Prescribing Information for PROVENGE. 10

12 Leukapheresis Procedure Facilitating treatment PROVENGE transforming therapy with Leukapheresis Procedure a regimen that is complete in 3 cycles Treatment can be completed in approximately 1 month 1 Median time was 28 days in the pivotal trial 1 PROVENGE is administered as 3 infusions, generally 2 weeks apart.* Each infusion is preceded by a standard leukapheresis procedure A Sample PROVENGE Schedule Leukapheresis Procedure Leukapheresis Procedure Leukapheresis Procedure Each infusion takes approximately 60 minutes. To help minimize infusion reactions such as chills and fever, approximately 30 minutes prior to infusion with PROVENGE, pretreat patients orally with acetaminophen and an antihistamine such as diphenhydramine 91.8% of patients in the PROVENGE group in the pivotal trial received a complete course of therapy. 2 PROVENGE is designed to stimulate the immune system: Concurrent use of chemotherapy or immunosuppressive agents (such as systemic corticosteroids) may alter efficacy and/or safety Carefully evaluate patients to determine whether it is medically appropriate to reduce or discontinue immunosuppressive agents prior to beginning treatment cycles *The dosing interval ranged from 1 to 15 weeks in controlled clinical trials. 1. Kantoff PW, Higano CS, Shore ND, et al; for the IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration The resistant precise prostate mechanism cancer. N Engl of J action Med. 2010;363: of PROVENGE is not known. 2. Data on file. Dendreon Corporation. 11 Please see Important Safety Information on page 6.

13 Handling the details One call activates Dendreon ON Call for support services throughout therapy Patient Assistance Programs Dedicated case managers to provide referrals to or information on: Independent foundations that may assist patients with co-pays, co-insurance, and deductible costs* Independent foundations that may assist patients with treatment-related travel costs* Reimbursement Support Dedicated case managers to help: Verify benefits Assist with prior authorizations Support claims appeals Provide referrals to local field personnel who can offer assistance with reimbursement related questions Product Support Dedicated case managers who: Generate patient schedules and leukapheresis reminder calls Ensure timely product ordering and delivery Handle product spoilage and returns Facilitate extended payment terms Please ask your Dendreon sales representative how to become an infusion site for PROVENGE therapy. Or, ask how you can refer patients to a site that has already been approved. *Co-pay and travel assistance foundations provide assistance regardless of the choice of medicine, and decisions are based on financial need and according to criteria established by individual foundations. Dendreon can assist patients by referring them to these independent organizations. Dendreon cannot guarantee that patients will be eligible for or receive assistance after referral. Dendreon does not have controlling or managerial influence on these independent organizations. Services vary by office based on application criteria and are subject to change or discontinuation. Stimulate a Response Please see enclosed full Prescribing Information for PROVENGE. 12

14

15

16 Stimulate an immune response against prostate cancer PROVENGE the first in a new class of therapy... Extends median survival beyond 2 years 25.8 months compared with 21.7 months for patients in the control group (P=.032) Therapy completed in 3 cycles 3 infusions, at approximately 2-week intervals* Most common adverse events are primarily mild or moderate chills, fatigue, fever, back pain, nausea, joint ache, and headache Survival (%) Overall Survival 1, months PROVENGE (n=341) Control (n=171) 25.8 months Time From Randomization (Months) Reduction in risk of death: 22.5% HR=0.775 (95% CI: 0.614, 0.979) P= Data originally published in the New England Journal of Medicine: Kantoff PW, Higano CS, Shore ND, et al; for the IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363: INDICATION: PROVENGE (sipuleucel-t) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. IMPORTANT SAFETY INFORMATION: PROVENGE is intended solely for autologous use and is not routinely tested for transmissible infectious diseases. In controlled clinical trials, serious adverse events reported in the PROVENGE group include acute infusion reactions (occurring within 1 day of infusion) and cerebrovascular events. Severe (Grade 3) acute infusion reactions were reported in 3.5% of patients in the PROVENGE group. Reactions included chills, fever, fatigue, asthenia, dyspnea, hypoxia, bronchospasm, dizziness, headache, hypertension, muscle ache, nausea, and vomiting. No Grade 4 or 5 acute infusion reactions were reported in patients in the PROVENGE group. The most common adverse events (incidence 15%) reported in the PROVENGE group are chills, fatigue, fever, back pain, nausea, joint ache, and headache. Please see enclosed full Prescribing Information for PROVENGE. * The dosing interval ranged from 1 to 15 weeks in controlled clinical trials. 1. PROVENGE [package insert]. Dendreon Corporation; April Kantoff PW, Higano CS, Shore ND, et al; for the IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363: Dendreon Corporation. All rights reserved. January Printed in the U.S.A. Dendreon, the Dendreon logo, and PROVENGE are registered trademarks of Dendreon Corporation. P-A Stimulate a Response

Page 1 of 19 - - - - - - - - - CONTRAINDICATIONS - - - - - - - - None. (4)

Page 1 of 19 - - - - - - - - - CONTRAINDICATIONS - - - - - - - - None. (4) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all of the information needed to use PROVENGE (sipuleucel-t) safely and effectively. See full prescribing information for PROVENGE.

More information

Phone: 1-877-336-3736 Fax: 1-877-556-3737 M F 8:00 am 9:00 pm ET

Phone: 1-877-336-3736 Fax: 1-877-556-3737 M F 8:00 am 9:00 pm ET QUICK REFERENCE CODING & BILLING GUIDE PHYSICIAN OFFICE CMS National Coverage Determination and Q-Code for PROVENGE Simplifies patient coverage criteria Clarifies coding requirements Expedites electronic

More information

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY Original Issue Date (Created): January 1, 2011 Most Recent Review Date (Revised): November 25, 2014 Effective Date: February 1, 2015 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS

More information

Evaluation of Treatment Pathways in Oncology: An Example in mcrpc

Evaluation of Treatment Pathways in Oncology: An Example in mcrpc Evaluation of Treatment Pathways in Oncology: An Example in mcrpc Sonja Sorensen, MPH United BioSource Corporation Bethesda, MD 1 Objectives Illustrate selection of modeling approach for evaluating pathways

More information

Advances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG 99-16 study results presented at ASCO 2004

Advances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG 99-16 study results presented at ASCO 2004 Ronald de Wit Rotterdam Cancer Institute The Netherlands Advances In Chemotherapy For Hormone Refractory Prostate Cancer TAX 327 study results & SWOG 99-16 study results presented at Slide 1 Prostate Cancer

More information

Incorporating Xofigo (radium Ra 223 dichloride) into Clinical Practice

Incorporating Xofigo (radium Ra 223 dichloride) into Clinical Practice Incorporating Xofigo (radium Ra 223 dichloride) into Clinical Practice Please see Important Safety Information throughout this presentation and full Prescribing Information available at this 2014 Bayer

More information

Issues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC)

Issues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC) Issues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC) FDA Presentation ODAC Meeting September 14, 2011 1 Review Team Paul G. Kluetz,

More information

Kanıt: Klinik çalışmalarda ZYTIGA

Kanıt: Klinik çalışmalarda ZYTIGA mkdpk de Sonunda Gerçek İlerleme! Kanıt: Klinik çalışmalarda ZYTIGA Dr. Sevil Bavbek 5. Türk Tıbbi Onkoloji Kongresi Mart 214, Antalya Endocrine therapies Adrenals Testis Abiraterone Orteronel Androgen

More information

Background. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4

Background. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4 Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.

More information

Prostate Cancer Studies

Prostate Cancer Studies Prostate Cancer Studies STUDIES CURRENTLY RECRUITING MDV3100-14 A multinational, Phase 3, Randomized, Double- Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastic

More information

Establishing an Advanced Prostate Cancer Clinic: The Rationale

Establishing an Advanced Prostate Cancer Clinic: The Rationale The information, views and opinions expressed in this presentation and any accompanying materials are those of the speaker and do not necessarily reflect the views or position of Cardinal Health or VitalSource.

More information

SIOG Guidelines Update 2014 Prostate Cancer. Dr Helen Boyle Centre Léon Bérard SIOG meeting 25 October 2014,Lisbon

SIOG Guidelines Update 2014 Prostate Cancer. Dr Helen Boyle Centre Léon Bérard SIOG meeting 25 October 2014,Lisbon SIOG Guidelines Update 2014 Prostate Cancer Dr Helen Boyle Centre Léon Bérard SIOG meeting 25 October 2014,Lisbon Droz JP, Aapro M, Balducci L, Boyle H, Van den Broeck T, Cathcart P, Dickinson L, Efstathiou

More information

January 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents

January 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for

More information

Prostate Cancer: Current Approach and Future Perspective in Castration-resistant Cancer Treatment

Prostate Cancer: Current Approach and Future Perspective in Castration-resistant Cancer Treatment Prostate Cancer: Current Approach and Future Perspective in Castration-resistant Cancer Treatment Abstract Prostate is one of the most commonly diagnosed solid tumours in males worldwide. Selection of

More information

Highlights in Advanced Prostate Cancer From the 2014 AUA and ASCO Meetings

Highlights in Advanced Prostate Cancer From the 2014 AUA and ASCO Meetings Highlights in Advanced Prostate Cancer From the 2014 AUA and ASCO Meetings A Review of Selected Presentations From the 2014 American Urological Association Meeting, May 16-21, 2014, Orlando, Florida and

More information

What s new in prostate cancer research? Highlights of GU-ASCO 2014

What s new in prostate cancer research? Highlights of GU-ASCO 2014 review What s new in prostate cancer research? Highlights of GU-ASCO 2014 Cite as: Can Urol Assoc J 2014;8(3-4Suppl2):S8-12. http://dx.doi.org/10.5489/cuaj.2013 Published online April 14, 2014. Abstract

More information

Prostate Cancer Vaccine Provenge : Is it really worth it? January 27, 2012

Prostate Cancer Vaccine Provenge : Is it really worth it? January 27, 2012 Prostate Cancer Vaccine Provenge : Is it really worth it? January 27, 2012 Diamond Thomas, Pharm.D. PGY-1 Community Practice Resident The University of Texas at Austin College of Pharmacy / H-E-B Pharmacy

More information

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line

More information

Updates in Prostate Cancer Therapy Sequencing Strategies. Debates and Didactics in Hematology and Oncology. July 26, 2015.

Updates in Prostate Cancer Therapy Sequencing Strategies. Debates and Didactics in Hematology and Oncology. July 26, 2015. Updates in Prostate Cancer Therapy Sequencing Strategies Debates and Didactics in Hematology and Oncology July 26, 2015. Sea Island, GA Bradley C. Carthon, MD. Ph.D. Assistant Professor, Winship Cancer

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

Thomas de los Reyes PGY 1 Department of Urologic Sciences University of British Columbia. Meet Mr. S

Thomas de los Reyes PGY 1 Department of Urologic Sciences University of British Columbia. Meet Mr. S Thomas de los Reyes PGY 1 Department of Urologic Sciences University of British Columbia Meet Mr. S 74 M admitted for back pain X-ray: sclerotic lesions along spine PSA 800 Nuclear Medicine Bone Scan 1

More information

GRANIX (tbo-filgrastim)

GRANIX (tbo-filgrastim) RATIONALE FOR INCLUSION IN PA PROGRAM Background Neutropenia is a hematological disorder characterized by an abnormally low number of neutrophils. A person with severe neutropenia has an absolute neutrophil

More information

NCCN Prostate Cancer Guidelines Update. James L. Mohler, MD Roswell Park Cancer Institute

NCCN Prostate Cancer Guidelines Update. James L. Mohler, MD Roswell Park Cancer Institute NCCN Prostate Cancer Guidelines Update James L. Mohler, MD Roswell Park Cancer Institute Every 2.5 Minutes an American is Diagnosed with Prostate Cancer Every 15 Minutes an American Dies of Prostate Cancer

More information

CLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15

CLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15 Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

More information

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing) Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the

More information

Il carcinoma prostatico metastatico: Quale prima linea? Quale terapia nelle linee successive? Claudia Caserta S.C. di Oncologia Terni

Il carcinoma prostatico metastatico: Quale prima linea? Quale terapia nelle linee successive? Claudia Caserta S.C. di Oncologia Terni Il carcinoma prostatico metastatico: Quale prima linea? Quale terapia nelle linee successive? Claudia Caserta S.C. di Oncologia Terni METASTATIC PROSTATE CANCER DIFFERENT THERAPEUTIC APPROACHES Metastatic

More information

THE MANY FACES OF MCRPC: ASSESSING PATIENT PROFILES AND TAILORING TREATMENT IN A CHANGING THERAPEUTIC LANDSCAPE

THE MANY FACES OF MCRPC: ASSESSING PATIENT PROFILES AND TAILORING TREATMENT IN A CHANGING THERAPEUTIC LANDSCAPE THE MANY FACES OF MCRPC: ASSESSING PATIENT PROFILES AND TAILORING TREATMENT IN A CHANGING THERAPEUTIC LANDSCAPE Summary of Presentations from the Bayer Healthcare Symposium, held at the 29 th Annual EAU

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Cancer Drug and Biological Products Clinical Data in Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and

More information

American Urological Association (AUA) Guideline

American Urological Association (AUA) Guideline 1 Approved by the AUA Board of Directors April 2015 Authors disclosure of potential conflicts of interest and author/staff contributions appear at the end of the article. 2015 by the American Urological

More information

Traitement médical du Cancer de la Prostate: du désert à la profusion. Prof. Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France

Traitement médical du Cancer de la Prostate: du désert à la profusion. Prof. Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Traitement médical du Cancer de la Prostate: du désert à la profusion Prof. Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation in advisory boards or as a speaker for:

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

7. Prostate cancer in PSA relapse

7. Prostate cancer in PSA relapse 7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined

More information

Ask your healthcare provider about LONG-ACTING AVEED (testosterone undecanoate) AVEED TESTOSTERONE INJECTION 5 SHOTS A YEAR. Not an actual patient.

Ask your healthcare provider about LONG-ACTING AVEED (testosterone undecanoate) AVEED TESTOSTERONE INJECTION 5 SHOTS A YEAR. Not an actual patient. Ask your healthcare provider about LONG-ACTING AVEED (testosterone undecanoate) AVEED TESTOSTERONE INJECTION 5 SHOTS A YEAR AFTER THE FIRST MONTH OF THERAPY Not an actual patient. CONSUMERS What is the

More information

PROSTATE CANCER 101 WHAT IS PROSTATE CANCER?

PROSTATE CANCER 101 WHAT IS PROSTATE CANCER? PROSTATE CANCER 101 WHAT IS PROSTATE CANCER? Prostate cancer is cancer that begins in the prostate. The prostate is a walnut-shaped gland in the male reproductive system located below the bladder and in

More information

Activity of pemetrexed in thoracic malignancies

Activity of pemetrexed in thoracic malignancies Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is

More information

Disease Modifying Therapies for MS

Disease Modifying Therapies for MS Disease Modifying Therapies for MS The term disease-modifying therapy means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks

More information

Should we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France

Should we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Should we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards/honorarium from: Amgen, Astellas,

More information

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015 Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future

More information

MEDIVATION, INC. FORM 8-K. (Current report filing) Filed 01/31/14 for the Period Ending 01/28/14

MEDIVATION, INC. FORM 8-K. (Current report filing) Filed 01/31/14 for the Period Ending 01/28/14 MEDIVATION, INC. FORM 8-K (Current report filing) Filed 1/31/14 for the Period Ending 1/28/14 Address 525 MARKET STREET 36TH FLOOR SAN FRANCISCO, CA 9415 Telephone 415-543-347 CIK 111835 Symbol MDVN SIC

More information

Potency Assays for an Autologous Active Immunotherapy (Sipuleucel-T) Pocheng Liu, Ph.D. Senior Scientist of Product Development Dendreon Corporation

Potency Assays for an Autologous Active Immunotherapy (Sipuleucel-T) Pocheng Liu, Ph.D. Senior Scientist of Product Development Dendreon Corporation Potency Assays for an Autologous Active Immunotherapy (Sipuleucel-T) Pocheng Liu, Ph.D. Senior Scientist of Product Development Dendreon Corporation Sipuleucel-T Manufacturing Process Day 1 Leukapheresis

More information

Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author

Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author Version History Policy Title Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: adoptive_immunotherapy 11/1993 3/2016 3/2017 3/2016 Description of Procedure or Service The spontaneous regression

More information

Presenter Disclosure Information

Presenter Disclosure Information Presenter Disclosure Information James L. Gulley MD PhD FACP The following relationships exist related to this presentation: The NCI has a Collaborative Research and Development Agreement (CRADA) with

More information

PROSTATE CANCER UPDATE. Presenter: Bruce W. Porterfield, MD, PhD

PROSTATE CANCER UPDATE. Presenter: Bruce W. Porterfield, MD, PhD PROSTATE CANCER UPDATE DISCLOSURES I, BRUCE WAYNE PORTERFIELD HAVE NOTHING TO DISCLOSE. OBJECTIVES Epidemiology Early detection and screening Review of clinical disease states Treatment options by disease

More information

Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer

Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single

More information

Analysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data

Analysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data The 2014 Cancer Program Annual Public Reporting of Outcomes/Annual Site Analysis Statistical Data from 2013 More than 70 percent of all newly diagnosed cancer patients are treated in the more than 1,500

More information

Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced

Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced September 27, 2013 ONO PHARMACEUTICAL CO., LTD. Corporate Communications Phone: +81-6-6263-5670 Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced

More information

Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate

Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate + Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma Claire Vines, 2016 Pharm.D. Candidate + Disclosure I have no conflicts of interest to disclose. + Objectives Summarize NCCN

More information

Drug/Drug Combination: Bevacizumab in combination with chemotherapy

Drug/Drug Combination: Bevacizumab in combination with chemotherapy AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy

More information

Guidance on competencies for management of Cancer Pain in adults

Guidance on competencies for management of Cancer Pain in adults Guidance on competencies for management of Cancer Pain in adults Endorsed by: Contents Introduction A: Core competencies for practitioners in Pain Medicine B: Competencies for practitioners in Pain Medicine

More information

What You Need to Know for Better Bone Health

What You Need to Know for Better Bone Health What You Need to Know for Better Bone Health A quick lesson about bones: Why healthy bones matter The healthier your bones The more active you can be Bone health has a major effect on your quality of life

More information

Niraparib (PARP Inhibitor) Phase 3 Pivotal Program for Ovarian Cancer February 14, 2013

Niraparib (PARP Inhibitor) Phase 3 Pivotal Program for Ovarian Cancer February 14, 2013 Niraparib (PARP Inhibitor) Phase 3 Pivotal Program for Ovarian Cancer February 14, 2013 Safe Harbor Statement Statements made in this presentation about TESARO, Inc. that are not descriptions of historical

More information

Disease Modifying Therapies for MS

Disease Modifying Therapies for MS Disease Modifying Therapies for MS The term disease-modifying therapy (DMT) means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks

More information

Epidemiology, Staging and Treatment of Lung Cancer. Mark A. Socinski, MD

Epidemiology, Staging and Treatment of Lung Cancer. Mark A. Socinski, MD Epidemiology, Staging and Treatment of Lung Cancer Mark A. Socinski, MD Associate Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive Cancer Center University of

More information

Your Certified Professional Cancer Coach. An Integrative Answer to Cancer Exclusive Professional Program for Patients with Cancer

Your Certified Professional Cancer Coach. An Integrative Answer to Cancer Exclusive Professional Program for Patients with Cancer Your Certified Professional Cancer Coach An Integrative Answer to Cancer Exclusive Professional Program for Patients with Cancer The CPCC Patient Program Nutrition & Lifestyle Oncology A Cancer Diagnosis

More information

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s

More information

UnitedHealthcare Injectable Chemotherapy Prior Authorization (PA) Program Frequently Asked Questions

UnitedHealthcare Injectable Chemotherapy Prior Authorization (PA) Program Frequently Asked Questions UnitedHealthcare Injectable Chemotherapy Prior Authorization (PA) Program Frequently Asked Questions Q1. What members are impacted by the UnitedHealthcare Injectable Chemotherapy PA Program? A. Beginning

More information

Types of Hypersensitivity

Types of Hypersensitivity Types of Hypersensitivity Type of Reaction Type I (anaphylactic) Type II (cytotoxic) Type III (immune complex) Type IV (delayed cellmediated) Time After Exposure for Clinical Symptoms

More information

CMScript. Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014

CMScript. Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014 Background CMScript Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014 Prostate cancer is second only to lung cancer as the leading cause of cancer-related deaths in men. It is

More information

Aggressive lymphomas. Michael Crump Princess Margaret Hospital

Aggressive lymphomas. Michael Crump Princess Margaret Hospital Aggressive lymphomas Michael Crump Princess Margaret Hospital What are the aggressive lymphomas? Diffuse large B cell Mediastinal large B cell Anaplastic large cell Burkitt lymphoma (transformed lymphoma:

More information

Riociguat Clinical Trial Program

Riociguat Clinical Trial Program Riociguat Clinical Trial Program Riociguat (BAY 63-2521) is an oral agent being investigated as a new approach to treat chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension

More information

Clinical Management Guideline Management of locally advanced or recurrent Renal cell carcinoma. Protocol for Planning and Treatment

Clinical Management Guideline Management of locally advanced or recurrent Renal cell carcinoma. Protocol for Planning and Treatment Protocol for Planning and Treatment The process to be followed in the management of: LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA Patient information given at each stage following agreed information

More information

Robert Bristow MD PhD FRCPC

Robert Bristow MD PhD FRCPC Robert Bristow MD PhD FRCPC Clinician-Scientist and Professor, Radiation Oncology and Medical Biophysics, University of Toronto and Ontario Cancer Institute/ (UHN) Head, PMH-CFCRI Prostate Cancer Research

More information

Defining Response in Prostate Cancer Immunotherapy. Lawrence Fong! University of California, San Francisco!

Defining Response in Prostate Cancer Immunotherapy. Lawrence Fong! University of California, San Francisco! Defining Response in Prostate Cancer Immunotherapy Lawrence Fong! University of California, San Francisco! U!C! S!F! Prostate Cancer Clinical States Pre-chemotherapy Post-chemotherapy (Scher et al, JCO

More information

Prostate cancer is the most common cause of death from cancer in men over age 75. Prostate cancer is rarely found in men younger than 40.

Prostate cancer is the most common cause of death from cancer in men over age 75. Prostate cancer is rarely found in men younger than 40. A.D.A.M. Medical Encyclopedia. Prostate cancer Cancer - prostate; Biopsy - prostate; Prostate biopsy; Gleason score Last reviewed: October 2, 2013. Prostate cancer is cancer that starts in the prostate

More information

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck

More information

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been

More information

Clinical Study Report

Clinical Study Report An Open, Multi-Center, Phase II Clinical Trial to Evaluate Efficacy and Safety of Taxol (), UFT, and Leucovorin in Patients with Advanced Gastric Cancer Clinical Study Report 4F, No. 156, Jiankang Rd.,

More information

Active centers: 2. Number of patients/subjects: Planned: 20 Randomized: Treated: 20 Evaluated: Efficacy: 13 Safety: 20

Active centers: 2. Number of patients/subjects: Planned: 20 Randomized: Treated: 20 Evaluated: Efficacy: 13 Safety: 20 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov

More information

Clinical Spotlight in Breast Cancer

Clinical Spotlight in Breast Cancer 2015 European Oncology Congress in Vienna Clinical Spotlight in Breast Cancer Reference Slide Deck Abstract #1815 Impact of Palbociclib Plus Fulvestrant on Global QOL, Functioning, and Symptoms Compared

More information

CABOZANTINIB VERSUS EVEROLIMUS IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA: RESULTS OF A RANDOMISED PHASE III TRIAL (METEOR)

CABOZANTINIB VERSUS EVEROLIMUS IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA: RESULTS OF A RANDOMISED PHASE III TRIAL (METEOR) CABOZANTINIB VERSUS EVEROLIMUS IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA: RESULTS OF A RANDOMISED PHASE III TRIAL (METEOR) This late-breaking abstract was presented on 26 th September 215 in Presidential

More information

Metastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011

Metastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011 Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare

More information

CheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early

CheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early April 21, 2015 CheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early Opdivo Demonstrates Superior Overall Survival Compared to Docetaxel in Patients with Previously-Treated

More information

Prostate Cancer. There is no known association with an enlarged prostate or benign prostatic hyperplasia (BPH).

Prostate Cancer. There is no known association with an enlarged prostate or benign prostatic hyperplasia (BPH). Prostate Cancer Definition Prostate cancer is cancer that starts in the prostate gland. The prostate is a small, walnut-sized structure that makes up part of a man's reproductive system. It wraps around

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description

More information

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT

More information

People Living with Cancer

People Living with Cancer Patient Guide ASCOInformation for People Living with Cancer HORMONE THERAPY FOR ADVANCED PROSTATE CANCER Recommendations of the American Society of Clinical Oncology Welcome The American Society of Clinical

More information

Novartis Gilenya FDO Program Clinical Protocol and Highlights from Prescribing Information (PI)

Novartis Gilenya FDO Program Clinical Protocol and Highlights from Prescribing Information (PI) Novartis Gilenya FDO Program Clinical Protocol and Highlights from Prescribing Information (PI) Highlights from Prescribing Information - the link to the full text PI is as follows: http://www.pharma.us.novartis.com/product/pi/pdf/gilenya.pdf

More information

Radiotherapy in locally advanced & metastatic NSC lung cancer

Radiotherapy in locally advanced & metastatic NSC lung cancer Radiotherapy in locally advanced & metastatic NSC lung cancer Dr Raj Hegde. MD. FRANZCR Consultant Radiation Oncologist. William Buckland Radiotherapy Centre. Latrobe Regional Hospital. Locally advanced

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium pemetrexed 500mg infusion (Alimta ) No. (192/05) Eli Lilly 8 July 2005 The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS

More information

February 8, 2012. BLA 125320/28 Denosumab (Xgeva ) Amgen Inc. DISCLAIMER STATEMENT

February 8, 2012. BLA 125320/28 Denosumab (Xgeva ) Amgen Inc. DISCLAIMER STATEMENT FDA ODAC Briefing Document February 8, 2012 Denosumab (Xgeva ) Amgen Inc. DISCLAIMER STATEMENT The attached package contains background information prepared by the Food and Drug Administration (FDA) for

More information

BCCA Protocol Summary for Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using SUNItinib (SUTENT )

BCCA Protocol Summary for Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using SUNItinib (SUTENT ) BCCA Protocol Summary for Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using SUNItinib (SUTENT ) Protocol Code Tumour Group Contact Physician UGIPNSUNI Gastrointestinal Dr. Hagen

More information

First-line Hormone Therapy

First-line Hormone Therapy First-line Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised

More information

Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products

Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation

More information

BREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I

BREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I BREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I Overview Why is it important to understand breast cancer? Choosing wisely Appropriateness

More information

Media Release. Basel, 27 September 2015

Media Release. Basel, 27 September 2015 Media Release Basel, 27 September 2015 Two positive studies of Roche s investigational cancer immunotherapy atezolizumab in specific type of lung cancer presented at 2015 European Cancer Congress Phase

More information

Series 1 Case Studies Adverse Events that Represent Unanticipated Problems: Reporting Required

Series 1 Case Studies Adverse Events that Represent Unanticipated Problems: Reporting Required Welcome! This document contains three (3) series of Case Study examples that will demonstrate all four OHSU reporting categories (#1 4) as well as examples of events that are considered not reportable.

More information

Level 1. Nutrition & Lifestyle Oncology Certificate

Level 1. Nutrition & Lifestyle Oncology Certificate Level 1 Nutrition & Lifestyle Oncology Certificate ONE MODULE 1 A Cancer Diagnosis Learn what cancer is; how/why it develops; diagnostic tests; inflammatory/ hormonal connections; 5 most important steps

More information

Prostate Cancer. Ravi A. Madan, MD Clinical Director Genitourinary Malignancies Branch National Cancer Institute

Prostate Cancer. Ravi A. Madan, MD Clinical Director Genitourinary Malignancies Branch National Cancer Institute Prostate Cancer Ravi A. Madan, MD Clinical Director Genitourinary Malignancies Branch National Cancer Institute 1 Educational Objectives By the end of this session, participants should be able to Understand

More information

BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA)

BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA) BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA) Protocol Code Tumour Group Contact Physician UBRAVKAD Breast Dr Stephen Chia ELIGIBILITY:

More information

DECISION AND SUMMARY OF RATIONALE

DECISION AND SUMMARY OF RATIONALE DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Clofarabine in the treatment of relapsed acute myeloid leukaemia (AML) The application was for clofarabine to remain in

More information

Florida Clinical Trials Agreement

Florida Clinical Trials Agreement Florida Clinical Trials Agreement Agreement to Reduce Cancer Morbidity and Mortality in Florida The undersigned parties to this Florida Clinical Trials Agreement (Agreement) acknowledge that Florida ranks

More information

Prostate Cancer Treatment: What s Best for You?

Prostate Cancer Treatment: What s Best for You? Prostate Cancer Treatment: What s Best for You? Prostate Cancer: Radiation Therapy Approaches I. Choices There is really a variety of options in prostate cancer management overall and in radiation therapy.

More information

New Treatment Options for Breast Cancer

New Treatment Options for Breast Cancer New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of

More information

Avastin in Metastatic Breast Cancer

Avastin in Metastatic Breast Cancer Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche

More information

A Woman s Guide to Prostate Cancer Treatment

A Woman s Guide to Prostate Cancer Treatment A Woman s Guide to Prostate Cancer Treatment Supporting the man in your life Providing prostate cancer support and resources for women and families WOMEN AGAINST PROSTATE CANCER A Woman s Guide to Prostate

More information

Oncology Medical Home: Strategies for Changing What and How We Pay for Oncology Care

Oncology Medical Home: Strategies for Changing What and How We Pay for Oncology Care Oncology Medical Home: Strategies for Changing What and How We Pay for Oncology Care John Fox, MD MHA Senior Medical Director Priority Health 1 Cancer Care is the Leading Edge of Medical Cost Trend for

More information

Trials in Elderly Melanoma Patients (with a focus on immunotherapy)

Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Where we were Immunotherapy Trials: past and present Relevance for real world practice Where we are SIOG October 2012 James Larkin FRCP

More information

Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation: Questions and Answers. Key Points

Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation: Questions and Answers. Key Points CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Bone Marrow Transplantation

More information